Smartlab Europe

Drug Research

Cancer drug screening process saves discovery time and limits use of mice

A method of testing drugs thatprompt the immune system to attack and destroy cancer cells has been developed which can speed up drug discovering andreducethe unnecessary use of mice in drug screening programmes. Certain cancer drugs help the body’s immune...

Recipharm and LIDDS establish industrial manufacturing capabilities for a novel prostate cancer product

Recipharm, the contract development and manufacturing organisation (CDMO), and LIDDS have together set up a manufacturing line for LIDDS’ novel prostate cancer drug, Liproca® Depot, at Recipharm in Solna, Sweden. The manufacturing line is dedicated to...

Asia Precision Medicine Research Array For Regional Screening Initiatives Announced By Thermo Fisher Scientific

Epidemiologists conducting national precision medicine initiatives focused on gathering clinical research data on genetic variation among East and South Asian populations now have access to Thermo Fisher Scientific's Applied Biosystems Axiom Asia Precision Medicine Research Array. ...

Abbvie and principia announce collaboration on oral immunoproteasome inhibitors

AbbVie , a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company, announced today that they have entered a collaboration for the development of oral immunoproteasome inhibitors. The collaboration is aimed at developing...

Thermo Fisher Scientific and SRI International Collaborate to Enhance Small Molecule Research

Thermo Fisher Scientific Inc., the world leader in serving science, and SRI International, a research center that creates world-changing solutions, today announced the results of a collaboration agreement to enable researchers to combine the results of high-resolution Orbitrap LC/MS...

eTheRNA advances in-vivo mRNA cancer immunotherapy into first oncology clinical studies

eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology clinical study evaluating its novel candidate TriMix-MEL (ECI-006) in metastatic melanoma patients showing no evidence...

Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China

Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. No...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »